levobetaxolol levobetaxolol levobetaxolol is a drug used to lower the pressure in the eye in treating conditions such as glaucoma. it is marketed as a 0.25 or 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name betaxon. levobetaxolol is a beta-adrenergic receptor inhibitor (beta blocker). levobetaxololclinical dataahfs/drugs.commicromedex detailed consumer informationroutes ofadministrationtopical (ophthalmic)atc codenonepharmacokinetic dataelimination half-life20 hoursidentifiers iupac name (s)-1-phenoxy]-3-(isopropylamino)-2-propanol hydrochloride cas number93221-48-8 npubchem cid60657iuphar/bps8035chemspider54669 yunii75o9xha4tuchebichebi:59254 ychemblchembl1201274 ncomptox dashboard (epa)dtxsid30239341 chemical and physical dataformulac18h29no3molar mass307.434 g·mol−13d model (jsmol)interactive image smiles o(ccc1ccc(oc(o)cnc(c)c)cc1)cc2cc2 inchi inchi=1s/c18h29no3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20h,3-4,9-13h2,1-2h3/t17-/m0/s1 ykey:nwiutzdmdhavtp-krwdzbqosa-n y ny (what is this?) (verify) indications it is indicated for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension. effect levobetaxolol inhibits the beta-1-adrenergic receptor. when applied topically, it reduces intra-ocular pressure (iop) by 16-23% depending on time of day and the individual. it also has neuroprotective effects. levobetaxolol has fewer cardiovascular side effects than other beta blockers. contraindications and side effects levobetaxolol should not be used by people who have sinus bradycardia, atrioventricular block, cardiogenic shock, or overt cardiac failure. the drug has been associated with bradycardia and hypertension. history levobetaxolol was developed in the 1980s. it was fda approved in 2000.